Non Small Cell Lung Cancer

Targeted therapies beneficial in KRAS-mutated NSCLC

(HealthDay)—Targeted therapies that do not contain erlotinib can be beneficial for patients with KRAS-mutated (KRAS mut+) advanced non-small-cell lung cancer (NSCLC), according to a study published online Aug. 1 in the ...

Aug 03, 2016
popularity3 comments 0

Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy is increasingly being used both pre-operatively (neoadjuvant chemotherapy) and post-operatively (adjuvant chemotherapy).

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

New trials offer hope for TB treatment

Researchers at the University of St Andrews are one step closer to finding a shorter, more effective treatment for TB, according to a new paper published by The Lancet Infectious Diseases.